Patient and disease characteristics by ethnicity in the SEER and validation cohorts
| . | SEER cohort . | Bronx validation cohort . | ||||
|---|---|---|---|---|---|---|
| Hispanic (n = 2664) . | Non-Hispanic white (n = 20 905) . | P . | Hispanic (n = 73) . | Non-Hispanic white (n = 79) . | P . | |
| Median age, y (range) | 59 (18-102) | 71 (18-111) | <.001 | 59 (21-88) | 71 (22-96) | <.001 |
| Sex, male | 1432 (53.8) | 11 540 (55.2) | .16 | 30 (41.1) | 35 (44.3) | .69 |
| Cytogenetic risk* | — | — | <.001 | — | — | .28 |
| Favorable | 104 (3.9) | 536 (2.6) | — | 5 (6.9) | 2 (2.5) | — |
| Intermediate | — | — | — | 28 (38.4) | 31 (39.2) | — |
| Poor | 2560 (96.1) | 20 369 (97.4) | — | 24 (32.9) | 20 (25.3) | — |
| Unknown | — | — | — | 16 (21.9) | 26 (32.9) | — |
| s-AML | — | — | — | 22 (30.1) | 37 (46.8) | .04 |
| Therapy | — | — | — | — | — | .08 |
| None/Bsc | — | — | — | 7 (9.6) | 9 (11.4) | — |
| ICT | — | — | — | 48 (65.8) | 39 (49.4) | — |
| HMT | — | — | — | 0 (0.0) | 4 (5.1) | — |
| Unknown | — | — | — | 18 (24.7) | 27 (34.2) | — |
| . | SEER cohort . | Bronx validation cohort . | ||||
|---|---|---|---|---|---|---|
| Hispanic (n = 2664) . | Non-Hispanic white (n = 20 905) . | P . | Hispanic (n = 73) . | Non-Hispanic white (n = 79) . | P . | |
| Median age, y (range) | 59 (18-102) | 71 (18-111) | <.001 | 59 (21-88) | 71 (22-96) | <.001 |
| Sex, male | 1432 (53.8) | 11 540 (55.2) | .16 | 30 (41.1) | 35 (44.3) | .69 |
| Cytogenetic risk* | — | — | <.001 | — | — | .28 |
| Favorable | 104 (3.9) | 536 (2.6) | — | 5 (6.9) | 2 (2.5) | — |
| Intermediate | — | — | — | 28 (38.4) | 31 (39.2) | — |
| Poor | 2560 (96.1) | 20 369 (97.4) | — | 24 (32.9) | 20 (25.3) | — |
| Unknown | — | — | — | 16 (21.9) | 26 (32.9) | — |
| s-AML | — | — | — | 22 (30.1) | 37 (46.8) | .04 |
| Therapy | — | — | — | — | — | .08 |
| None/Bsc | — | — | — | 7 (9.6) | 9 (11.4) | — |
| ICT | — | — | — | 48 (65.8) | 39 (49.4) | — |
| HMT | — | — | — | 0 (0.0) | 4 (5.1) | — |
| Unknown | — | — | — | 18 (24.7) | 27 (34.2) | — |
Data are presented as n (%) of patients unless otherwise indicated.
Bsc, best supportive care; HMT, hypomethylating agent; ICT, intensive chemotherapy, s-AML, antecedent hematological disorder and therapy related AML.
Two cytogenetic risk categories were generated because of incomplete information on cytogenetics in the SEER cohort: (1) favorable (to include AML with t(8;21), inv(16), and t(16;16)) and (2) all other.